Hemolytic disease of the fetus and newborn (HDFN) is closely tied to an increased risk of necrotizing enterocolitis (NEC), a severe intestinal disorder that can be fatal for infants. Research shows that both the disease itself and its treatments can make NEC more likely, meaning parents and doctors must weigh the benefits and risks of care options, according to a mini-review published recently in Frontiers in Pediatrics.
HDFN occurs when a mother’s blood type is incompatible with that of her baby, most often from Rh or ABO mismatches. This causes the infant’s red blood cells to be destroyed, leading to anemia, jaundice, and other complications.
“As a life-threatening condition, early identification and intervention targeting these risk factors are crucial for improving outcomes,” the authors of this review stated regarding HDFN.
Severe anemia can lower oxygen supply to the intestines, damaging the gut lining and making NEC more likely. Studies have found that babies with hemoglobin levels at or below 8 g/dL were nearly six times more likely to develop NEC compared with healthier infants.
Read more about the prognosis of HDFN
Changes in blood clotting also play a role. Red blood cell breakdown in HDFN releases substances that make clotting more likely, sometimes leading to small blood vessel blockages in the intestines. These blockages can cut off blood flow and trigger intestinal tissue death, a key feature of NEC. Research in more than 200 newborns with ABO-related HDFN found that higher clotting activity was strongly linked to NEC.
Treatments that save lives in HDFN may unintentionally worsen gut risk. Phototherapy, a common treatment for jaundice, can alter blood flow in the intestines, disturb gut bacteria, and cause dehydration, all of which make NEC more likely. In one study, babies who had more than 120 hours of phototherapy or more than four rounds of treatment faced a significantly higher risk of NEC.
Intravenous immunoglobulin (IVIG), another widely used therapy, can reduce the need for risky blood exchanges. But some research shows high-dose IVIG may thicken the blood and damage blood vessels, leading to intestinal injury. In one study of nearly 500 newborns, 2.2% of those receiving high-dose IVIG developed NEC, compared with just 0.3% in the control group.
Blood transfusions and double-volume exchange transfusions, while essential for treating severe anemia and jaundice, also carry risks. These procedures may reduce protective blood vessel relaxation in the intestines, leading to hypoxia and injury. Some studies suggest pausing feedings during transfusions may lower NEC risk, though the safest strategies for babies with HDFN remain unclear.
For families, this research highlights the importance of close monitoring and careful treatment planning when managing HDFN. While therapies are often necessary to prevent life-threatening complications, understanding their potential effects on the gut may help doctors better protect newborns from NEC.
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
